Clinical Trials

6 enrolled 17 charts

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

4 enrolled

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

45 enrolled

Multiple Myeloma, Recurrence

NCT02963610 2021-12-30

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

3 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01729104 2019-10-22

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Phase 1 Terminated

18 enrolled

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02075021 2018-10-15

rev/abraxane

3 enrolled 3 charts

Multiple Myeloma, Recurrence

NCT00538824 2018-06-06

DexTR

5 enrolled 8 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02983097 2018-01-19

R²-DHAP

34 enrolled

Burkitt Lymphoma, Lymphoma, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01121757 2016-09-12

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

11 enrolled 12 charts

Lymphoma, Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT00968331 2012-08-27

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

25 enrolled